Your browser doesn't support javascript.
loading
DTL is a Novel Downstream Gene of E2F1 that Promotes the Progression of Hepatocellular Carcinoma.
Dong, Ruiqiang; Zhang, Danhua; Han, Baowei; Xu, Lingxue; Zhang, Danfeng; Cheng, Zhenguo; Qiu, Xinguang.
Affiliation
  • Dong R; Department of General Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Zhang D; Department of General Surgery, The Affiliated Luoyang Central Hospital of Zhengzhou University, Luoyang, China.
  • Han B; Department of General Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Xu L; Department of General Surgery, The Affiliated Luoyang Central Hospital of Zhengzhou University, Luoyang, China.
  • Zhang D; National Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
  • Cheng Z; Department of General Surgery, The Affiliated Luoyang Central Hospital of Zhengzhou University, Luoyang, China.
  • Qiu X; National Center for International Research in Cell and Gene Therapy, Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
Curr Cancer Drug Targets ; 23(10): 817-828, 2023.
Article de En | MEDLINE | ID: mdl-37171007

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome hépatocellulaire / Tumeurs du foie Limites: Humans Langue: En Journal: Curr Cancer Drug Targets Sujet du journal: ANTINEOPLASICOS / NEOPLASIAS Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: Pays-Bas

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome hépatocellulaire / Tumeurs du foie Limites: Humans Langue: En Journal: Curr Cancer Drug Targets Sujet du journal: ANTINEOPLASICOS / NEOPLASIAS Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: Pays-Bas